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North Carolina macular dystrophy (NCMD) is an autosomal dominant macular disease, was mapped to 6q14-q16.2, the disease-caus-
ing gene has yet not been identiﬁed. It shares phenotypic similarity with age-related macular degeneration including drusen and choroidal
neovascularization. We collected six families with NCMD including 75 members, and conducted clinical characterization and genetic
mapping for these families. Forty-ﬁve patients were diagnosed as NCMD; all six NCMD families were mapped to MCDR1 locus using
genetic linkage analysis. MCDR1 interval was reﬁned to 3 cM (1.8mb) between D6S1716 to D6S1671 via ﬁne mapping using microsat-
ellite markers in these six families, all eleven annotated genes within the interval were analyzed by mutation screening in coding regions,
no mutation was found, suggesting a potential novel gene or a new pathological mechanism causing NCMD. The reﬁnement of MCDR1
locus will aid the disease-causing gene identiﬁcation. Functional studies of NCMD genes should provide important insights into path-
ogenetic mechanisms of NCMD and age-related macular degeneration.
 2007 Elsevier Ltd. All rights reserved.
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The inherited macular dystrophies are characterized by
bilateral visual loss and the ﬁnding of generally symmetrical
macular abnormalities, they can present as genetic hetero-
geneity including autosomal dominant, autosomal reces-
sive, X linked recessive and mitochondrial inheritance.
NCMD is an autosomal dominant, highly penetrant disease
with congenital or infantile onset. NCMD shares many0042-6989/$ - see front matter  2007 Elsevier Ltd. All rights reserved.
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1 These authors contributed equally to this work.important clinical and histopathological similarities with
AMD including an abnormal accumulation of drusen, atro-
phy of the RPE and overlying photoreceptor cells, choroi-
dal neovascularizatioon and loss of central vision (Small,
Hermsen, Gurney, Fetkenhour, & Folk, 1992). Leﬂer,
Wadsworth, and Sidbury (1971) reported a large family
with multiple generations from North Carolina that was
aﬀected with a form of drusen and macular degeneration,
therefore the term North Carolina macular dystrophy.
North Carolina macular dystrophy has been described
under diﬀerent names such as central areolar pigment epi-
thelial dystrophy (CAPED), central pigment epithelial and
choroidal degeneration, and central retinal pigment epithe-
lial dystrophy in several branches of a large family (Frank,
Landers, Williams, & Sidbury, 1974; Small, Hermsen et al.,
1992). The disease in this family was apparently inherited
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eighteenth and early nineteenth centuries (Frank et al.,
1974; Small, Hermsen et al., 1992). It is generally non-pro-
gressive and shows a wide range of intrafamilial and inter-
familial variations in clinical phenotypes. These clinical
manifestations can be divided into three grades. Grade I
represents drusen in the central macula. Grade II denotes
subretinal neovascularization or scar. Grade III exhibits
well-demarcated chorioretinal atrophy with hyperpigmen-
tation on the edge of the lesion. A large family with North
Carolina macular dystrophy inherited as an autosomal
dominant, fully penetrant trait was studied. Linkage analy-
sis of this kindred, now known to include more than 2000
individuals, localized the disease-causing gene to chromo-
some 6q16 between D6S275 and D6S475 in a 4.5 cM inter-
val. This locus has been designated by Online Mendelian
Inheritance of Man (OMIM) as MCDR1, for macular
degeneration locus 1 (OMIM #136550) (Small et al.,
1999; Small, Weber, Roses, & Pericak-Vance, 1993; Small,
Weber et al., 1992). Several European and South American
families with a NCMD phenotype were also localized to the
MCDR1 locus, supporting its role as a signiﬁcant cause of
childhood macular degeneration (Rabb, Mullen, Yelchits,
Udar, & Small, 1998; Reichel et al., 1998; Sauer et al.,
1997; Small, Garcia, Gallardo, Udar, & Yelchits, 1998;
Small, Puech, Mullen, & Yelchits, 1997). We performed
clinic study and linkage mapping in six families with
NCMD and reﬁned MCDR1 to 1.8 million base pairs.2. Methods
2.1. Study subjects
This project was approved by the Institutional Board of the Institute of
Ophthalmology and the Institutional Review Board of the University of
Utah Health Science Center, USA. Informed consent was obtained from
all participants. Seventy ﬁve members from six families were included; all
participatants underwent ophthalmic examination including best corrected
Snellen visual acuity determination and fundus examination. Fluorescein
angiographywas carried out on some patients. Aﬀected patients were desig-
nated on the basis of decrease visual acuity and the macular lesions.
2.2. Establishment of cell lines and DNA and RNA isolation
Blood was collected by venepuncture, Lymphoblastoid cell lines
were established by Epstein-Bar virus transformation of peripheral
mononuclear cells as previously described (Chou et al., 1992). Haploid
somatic hybrids cell lines were established using a GMP Conversion
Technology (Yan, Papadopoulos et al., 2000). Genomic DNA and
RNA was isolated from the blood samples, EBV-transformed lympho-
blastoid cells and haploid somatic hybrids using a Puregene genomic
DNA puriﬁcation kit or VERSAGENETM RNA Kit (Gentra Systems,
Minneapolis, Massachusetts, USA). cDNA was made using Super-
ScriptTM III First-Strand Synthsis Sytem for RT-PCR (Invitrogen Cor-
poration, Carlsbad, CA).
2.3. Genotyping and linkage analysis
In order to obtain a high density coverage of STR markers in the Min-
imum Genetic Interval (MGI), we ﬁrst determined the precise physical
location of each known STR marker listed on the Marshﬁeld genetic maps(http://research.marshﬁeldclinic.org/genetics/GeneticResearch/compM-
aps.asp) by using public NCBI (http://www.ncbi.nlm.nih.gov/) and UCSC
(http://genome.ucsc.edu/) databases (Table 1). To generate additional
STR markers, we searched genomic DNA sequences from public NCBI
and UCSC databases and identiﬁed 30 potential candidates. These poten-
tial STR markers included CA, ATA, GATA, GAAG repeats. We then
tested the degree of polymorphisms of these STR markers by genotyping
them on six North Carolina macular dystrophy families and 100 unrelated
Caucasian individuals.
Twenty-six of these 30 STR markers appeared to be informative and
highly polymorphic and were used in genotyping analyses (Table 1). This
approach allowed us to saturate the MGI with STR markers with an aver-
age coverage of 100 kb between two STR markers and determine the lin-
ear order of markers (Table 1).
Thirty STR markers were genotyped using the primers either found
from Marshﬁeld Clinic or designed by ourselves. The genotyping was per-
formed using P32 labeling method using genomic DNA isolated from
blood (Yang et al., 2002; Zhang et al., 2001). Two-point LOD scores were
calculated using the subroutine MLINK of the LINKAGE program
(v.5.1; http://www.hgmp.mrc.ac.uk/; Human Genome Mapping Project
Resources Center, Cambridge, UK) (Lathrop, Lalouel, Julier, & Ott,
1984; Lathrop, Lalouel, Julier, & Ott, 1985). An autosomal-dominant
mode of inheritance with full penetrance and a disease allele frequency
of 0.0001 were assumed in the computations.2.4. Sequencing analysis
Exons and cDNAs of POU3F2, FBXL4, LOC389416, C6orf168,
COQ3, C6orf111, USP45, LOC401270, CCNC, PRDM13 and MCHR2
were PCR ampliﬁed and subject to sequencing analysis. For exons ampli-
ﬁcation of each gene, we use genomic DNA from blood and haploid
somatic hybrids. We used RNA from EBV-transformed lymphoblastoid
cell lines and haploid somatic hybrids cell lines to perform RT-PCR. All
PCR products were puriﬁed using a QIAquick Gel Extraction Kit (QIA-
GEN Science, MD, USA) and sequenced using Big Dye Terminator v3.1
Cycle Sequencing Kit (ABI, Foster City, CA, USA).3. Results
3.1. Clinical evaluation
Six multiple generation pedigrees (324, 348, 71, 633, 419,
and 3784) with NCMD were identiﬁed for study (Fig. 1).
Family 324, 348, 71, 633 and 3784 are of Caucasian origin
whereas family 419 is of Chinese origin. These pedigrees
revealed autosomal dominant inheritance, with aﬀected
members in each generation. Clinical evaluation and
genetic studies on Family 324 were previously published
(Reichel et al., 1998). Family 3784 was referred by an oph-
thalmologist with documented fundus photographs on
aﬀected patients. Thus careful clinical evaluations were per-
formed in every individual to ensure an accurate diagnosis.
A complete ophthalmic history and examination was per-
formed on each patient. This included assessment of visual
acuity, and detailed examination of the anterior segment
and fundus. Individuals were diagnosed to be aﬀected if
they had decreased visual acuity along with macular atro-
phy, or if drusen were found in the posterior pole. Color
fundus photographs were obtained for all aﬀected individ-
uals. At least four aﬀected individuals in each kindred
underwent ﬂuorescein angiography. Forty two aﬀected
patients in NCMD families demonstrated a wide range of
Table 1
Fine Genetic map and list of polymorphic DNA markers
STR Marker Repeats Location(mb) Recombination BAC ID
Family 663 Family 348 Family 324 Family 71
D6S249 AG/CT 98.22 U X U U AL596208
D6S1284 AAGG/CCTT 98.82 U X U U AL589740
D6S1716 CA/TG 98.85 U X U U AL589740
S3-34301 CA/TG 99.01 U U U U AL607071
S3-201660 AAGG/CCTT 99.18 U U U U AL590395
S3-188835 CA/TG 99.27 U U U U AL590395
S3-263101 CA/TG 99.34 U U U U AL590395
S3-328991 CA/TG 99.41 U U U U AL589826
S4-674 CA/TG 99.48 U U U U AL022395
S4-40977 CA/TG 99.52 U U U U AL078603
S4126261 CA/TG 99.61 U U U U AL078603
S4-198781 TA/TA 99.68 U U U U AL59022
D6S1717 CA/TG 99.78 U U U U AL591803
S4-364451 CA/TG 99.83 U U U U AL034371
D6S1565 CA/TG 99.84 U U U U AL034371
S4-398191 CA/TG 99.87 U U U U AL034371
S4-444001 CA/TG 99.91 U U U U AL513550
S5-162761 GAAA/TTTC 100.13 U U U U AL137784
S5-277706 CA/TG 100.25 U U U U AL035087
S5-336600 CA/TG 100.31 U U U U AL390959
S5-388393 CA/TG 100.36 U U U U AL390959
S5-433030 GAAA/TTTC 100.40 U U U U AL590725
S5-452941 AG/CT 100.42 U U U U AL590725
S6-34593 CA/TG 100.50 U U U U AL590725
D6S1671 CA/TG 100.66 U U U U AL080285
S6-170561 CA/TG 100.69 X U U U AL080285
D6S475 GATATATC 100.71 X U U U AL080285
Note. X denotes a recombination event between a marker and disease in an indicated family; U denotes no recombination between a marker and disease in
an indicated family. Information of BAC ID was obtained from NCBI, assembly of March 2006 of UCSC database was used for physical location.
472 Z. Yang et al. / Vision Research 48 (2008) 470–477clinical phenotypes, including conﬂuent drusen in the mac-
ula Fig. 2a, b, and d), choroidal neovascularization
(Fig. 2f, g, and h), subretinal scars (Fig. 2e), or macular
staphloma (Fig. 2c).
3.2. Generation of EBV-transformed lymphoblastoid cell
lines and haploid somatic hybrids
EBV transformed lymphoblastoid cell lines from three
aﬀected and two normal individuals in each kindred were
established. In addition, using a GMP Conversion Tech-
nology (Yan, Papadopoulos et al., 2000) we were able to
separate normal and MCDR1 containing chromosomes
and create haploid somatic hybrid cell lines (haploid sam-
ples) for one aﬀected patient in family 348, 324, 71, 633,
419 and 3784. Since there is no normal allele to mask a dis-
ease allele, haploid samples allow one to unambiguously
determine a disease haplotype, or identify a mutation
(Yan, Kinzler, & Vogelstein, 2000).
3.3. Genetic linkage analysis
Because the clinical features observed in family 348,
324, 71, 633, 419, and 3784 were characteristic of
NCMD, genetic linkage mapping for the responsible
gene was conducted using DNA markers linked to the
locus for MCDR1 on chromosomal 6q16 using estab-lished methods (Garibaldi & Zhang, 1999; Kniazeva
et al., 1999; Kniazeva et al., 2000). Positive linkage to
the MCDR1 locus was observed (Table 2). The likeli-
hood (two point lod scores) of linkage between locus
D6S1284, D6S1717, and D6S475 and the MCDR1 locus
was determined (Table 2). The maximum lod score, 15.8,
was achieved with marker D6S1717 at recombination
fraction 0. To further reﬁne the minimal genetic interval,
haplotypes of individuals in each family were analyzed
for recombination events. We genotyped additional 23
STR markers and identiﬁed haplotypes which segregated
with disease (Table 1). Individuals with recombinant
haplotypes are indicated (as an X) in Table 1. One
recombination event occurred at D6S249, D6S1284, and
D6S1716 in individual #0348004 of family 348 (Fig. 1
& Table 1), another occurred at D6S475 in individual
#0633001 of family 663 (Fig. 1 and Table 1). Therefore,
haplotype analyses suggest that the disease gene is most
likely located in the interval between locus D6S1716 and
D6S1671, corresponding to 1.86 million bps and contain-
ing 10 known or predicted genes (Table 1).3.4. Completion of a high-resolution genetic linkage map of
the MCDR1 locus
As the ﬁrst step in positional cloning of MCDR1, we
performed ﬁne linkage mapping in order to establish a
Z. Yang et al. / Vision Research 48 (2008) 470–477 473high-resolution genetic linkage map of the MCDR1 locus.
This approach allows us to reﬁne the MGI containing the
MCDR1 locus. Individuals showing recombination with
either D6S1716 or D6S475 were genotyped with new
STR markers. The result indicated that there are only
one recombination event between D6S1716 and theI:1 I:2
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474 Z. Yang et al. / Vision Research 48 (2008) 470–477ferent independent families are investigated. This analysis
is particularly useful to reﬁne a MGI due to an ancestral
founder mutation. We compared the disease allele of each
STR marker of six North Carolina macular dystrophy fam-
ilies to construct extended disease haplotypes (Fig. 1). Thisanalysis revealed that the family 348, 324, and 71 shared an
identical disease haplotype between D6S1284 and S6-
170561, indicating that they originated from an ancestral
founder mutation. However, haplotypes of these three fam-
ilies diverged at marker D6S1671. Therefore the MGI has
Fig. 2. Fundus photographs of aﬀected patients with North Carolina macular dystrophy, showing inter and intra familiar variations. (a) Patient #0348004
and (b) patient #0348008 in family 348, demonstrating ﬁne, conﬂuent drusen in the macula (Grade I). (c) Patient #0633001 in family 633, demonstrating a
macular staphloma (Grade III). (d) Patient #0633009 in family 633, demonstrating conﬂuent macular drusen (Grade I). (e and f) Right eye and left eye of
patient #0633004 in family 633, demonstrating a subretinal scar due to a prior choroidal neovasularization (CNV) in the right eye and a new CNV in the
left eye. (g and h) Early and late frames of ﬂuorescein angiography of the left eye of patient #0633004, demonstrating hyperﬂuorescence in the macula
corresponding to an active CNV.
Z. Yang et al. / Vision Research 48 (2008) 470–477 475been reﬁned to a region between marker D6S1716
(98.85 mb) and D6S1671 (100.66 mb), corresponding to
approximately 1.81 mb (Table 1).
3.5. The examination of candidate genes for MCDR1
A search for potential genes using public human genome
databases revealed 10 known or predicted genes within the1.8 million base pairs of interval (POU3F2, FBXL4,
LOC389416, C6orf168, COQ3, C6orf111, USP45,
LOC401270, CCNC, PRDM13 and MCHR2). All exons
and cDNA of the 11 genes were analyzed. Unfortunately,
we have not identiﬁed any DNA alteration in the coding
region or splicing junctions that provide convincing evi-
dence that they cause North Carolina macular dystrophy
phenotype.
Table 2
Two-point lod scores between STRs and disease phenotype
Recombination fractions 0 0.1 0.2 0.3 0.4
D6S1284
Family348 3.49 2.83 2.36 1.67 0.84
Family324 3.21 2.63 1.99 1.32 0.62
Family71 3.01 2.47 1.87 1.24 0.58
Family633 3.13 2.59 1.99 1.34 0.63
Total 5.86 10.5 8.21 5.57 2.67
S3-201660
Family348 4.12 3.41 2.65 1.82 0.93
Family324 3.3 2.7 2.03 1.31 0.58
Family71 3.01 2.46 1.85 1.19 0.53
Family633 2.11 1.7 1.26 0.8 0.34
Total 12.5 10.3 7.79 5.12 2.38
D6S1717
Family348 4.52 3.78 2.96 2.04 1.02
Family324 4.7 3.93 3.08 2.12 1.06
Family71 3.3 2.72 2.06 1.34 0.61
Family633 3.31 2.76 2.15 1.46 0.7
Total 15.8 12.7 10.3 6.96 3.39
S5-336600
Family348 2.71 2.07 1.37 0.67 0.15
Family324 2.9 2.22 1.47 0.72 0.16
Family71 0.81 0.63 0.5 0.38 0.22
Family633 2.38 1.94 1.47 0.97 0.46
Total 8.78 6.86 3.34 2.74 0.99
D6S475
Family348 3.51 2.9 2.24 1.52 0.77
Family324 3.65 3.01 2.32 1.58 0.8
Family71 2.71 2.21 1.65 1.05 0.45
Family633 13 1.15 1.29 0.89 0.42
Total 3.12 9.27 7.5 5.04 2.44
476 Z. Yang et al. / Vision Research 48 (2008) 470–4774. Discussion
Over the past decade, much progress has been made in
identifying genes for juvenile macular dystrophy. Many
loci for macular dystrophy have been mapped and six genes
cloned (Allikmets et al., 1997; Heon et al., 1996; Kniazeva
et al., 2000; Michaelides, Hunt, & Moore, 2003; Nichols
et al., 1993; Petrukhin et al., 1998; Sun, Molday, &
Nathans, 1999; Weber, Vogt, Wolz, Ives, & Ewing, 1994;
Wells et al., 1993; Weng et al., 1999; Zhang et al., 2001).
Functional studies of these genes have provided important
insights into pathogenetic mechanisms of macular degener-
ation. For example, ABCR is the protein product of the
recessive Stargardt macular dystrophy gene, ABCA4, that
functions as an outwardly directed ﬂippase for removal
of N-retinyliden-phosphatidylethanolamine (A2E, (Greg-
ory et al., 1996; Stone et al., 1999)). ELOVL4 is mutated
in dominant Stargardt macular dystrophy and encodes an
enzyme involved in elongation of very long chain fatty acid
(Cameron et al., 2007; Karan et al., 2005; Zhang et al.,
2001).
It is important to study the genetic basis of North Car-
olina macular dystrophy, as it causes juvenile macular
degeneration with visual impairment. Furthermore, the sig-
niﬁcance of proposed studies on North Carolina maculardystrophy lies in its relationship with AMD. North Caro-
lina macular dystrophy shares important clinical features
with age-related macular degeneration (AMD). Drusen is
a hallmark of AMD and choroidal neovascularization
(CNV) is one of the most important complications of
AMD. Both of them are present in patients with North
Carolina macular dystrophy. Therefore, these observations
make North Carolina macular dystrophy a unique genetic
model for AMD. NCDR1 was initially mapped to 6q16
and then reﬁned to an interval between D6S249 and
D6S1671 (Small, Weber et al., 1992; Small et al. 1999).
Through this study, we reﬁned MCDR1 interval to
1.81 mb between D6S1716 and D6S1671. No disease-caus-
ing mutation was identiﬁed in the candidate genes within
the interval suggesting that MCDR1 mutations may lie in
a novel gene or caused a new pathogenic mechanism.
Understanding the molecular mechanisms of MCDR1
should lead to novel insights into the pathogenesis of mac-
ular degeneration. Elucidation of the function of the
MCDR1 gene may increase our understanding of retinal
cell biology in general and drusen formation in particular.Acknowledgments
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